Ion channels are desirable therapeutic targets, yet ion channel-directed drugs with high selectivity and few side effects are still needed. Unlike small-molecule inhibitors, antibodies are highly selective for target antigens but mostly fail to antagonize ion channel functions. Nanobodies-small, single-domain antibody fragments-may overcome these problems. P2X7 is a ligand-gated ion channel that, upon sensing adenosine 5′-triphosphate released by damaged cells, initiates a proinflammatory signaling cascade, including release of cytokines, such as interleukin-1b (IL1b). To further explore its function, we generated and characterized nanobodies against mouse P2X7 that effectively blocked (13A7) or potentiated (14D5) gating of the channel. Systemic injection of nanobody 13A7 in mice blocked P2X7 on T cells and macrophages in vivo and ameliorated experimental glomerulonephritis and allergic contact dermatitis. We also generated nanobody Dano1, which specifically inhibited human P2X7. In endotoxin-treated human blood, Dano1 was 1000 times more potent in preventing IL-1b release than small-molecule P2X7 antagonists currently in clinical development. Our results show that nanobody technology can generate potent, specific therapeutics against ion channels, confirm P2X7 as a therapeutic target for inflammatory disorders, and characterize a potent new drug candidate that targets P2X7.
INTRODUCTION
Genetic and pharmacological studies in humans have implicated the adenosine 5′-triphosphate (ATP)-gated P2X7 ion channel as a therapeutic target in several inflammatory diseases, including glomerulonephritis, multiple sclerosis, and chronic pain (1) (2) (3) (4) . Consistently, studies with P2X7-deficient mice have also corroborated a key role of P2X7 in experimentally induced inflammatory diseases (5) (6) (7) (8) . P2X7 is prominently expressed by monocytes and T cells and responds to ATP released from damaged cells as a danger signal during inflammation (9, 10) . ATP-induced gating of P2X7 permits influx of calcium (Ca 2+ ) and sodium (Na + ) ions and efflux of potassium ions (K + ). P2X7 is a key player in the processing and release of the proinflammatory cytokine interleukin-1b (IL-1b) by lipopolysaccharide (LPS)-primed macrophages and is involved in the ectodomain shedding of membrane proteins and the externalization of phosphatidylserine by T cells (9, 11, 12) .
Selective small-molecule inhibitors of P2X7 have been developed for the treatment of inflammatory diseases by Pfizer (CE-224,535), AstraZeneca (AZ-10606120 and AZD9056), and other pharmaceutical companies (13) (14) (15) (16) . Many of these P2X7 antagonists have shown promising results in preclinical trials of glomerulonephritis, multiple sclerosis, inflammatory pain, rheumatoid arthritis, and mood disorders (13) (14) (15) (16) (17) (18) . However, the two compounds tested in phase 2 clinical trials for rheumatoid arthritis, AZD9056 and CE-224,535, did not show any benefit beyond that of methotrexate (NCT00520572 and NCT00628095) (19, 20) . Additional trials with AZD9056 for osteoarthritis, chronic obstructive pulmonary disease, and Crohn's disease showed a benefit only in Crohn's disease (Eudra-CT2005-002319-26) (21) . These studies illustrate the limitations of small-molecule P2X7 inhibitors, including a small therapeutic window, short in vivo halflife, side effects on other members of the P2X family, and conversion into ineffective and potentially toxic metabolites. Thus, an unmet medical need for potent, less toxic P2X7 antagonists remains (15, 18) .
Because of their exquisite specificity, low toxicity, and simple pharmacodynamics, antibodies are emerging as a potent class of therapeutics in autoimmunity, cancer, and infection. They are large, tetrameric proteins of~150 kDa that do not pass the renal filtration barrier and therefore exhibit a much longer half-life (>10 days) than small-molecule drugs. Current anti-inflammatory antibodies are directed against cytokines, cytokine receptors, and cell-cell interaction molecules. Although ion channels are potential therapeutic targets on immune cells for inflammatory diseases, they have remained underexplored as targets of antibody therapeutics (22) . Although conventional antibodies can diminish ion channel function by inducing endocytosis, they rarely directly interfere with ion channel function (22) . Because of a unique propensity to bind functional crevices on proteins (23) , nanobodies may fulfill the need for highly specific therapeutics toward ion channels (24, 25) .
Nanobodies are therapeutic proteins based on the smallest antigenbinding domains of naturally occurring heavy chain-only antibodies from camelids. These single-domain antibodies are 1 / 10 the size of conventional antibodies and exhibit many advantages over conventional antibodies (26, 27) . With a long flexible CDR3 loop, nanobodies can bind conformational epitopes that are inaccessible to conventional 1 antibodies, such as the cryptic active site of an enzyme (24, 25) . Moreover, the single-domain format of nanobodies facilitates the construction of multispecific and multivalent biologics by genetically linking nanobodies in a linear fashion (25, 27) . In vivo, monomeric nanobodies penetrate tissues better and more rapidly than conventional antibodies but are swiftly eliminated by renal filtration. The in vivo half-life of mono-or multivalent nanobodies can be tuned, for instance by genetic fusion to an albumin-specific nanobody (28) . Similarly, genetic fusion with targeting moieties of Fc domains can endow nanobodies with additional effector functions, from translocation across the blood-brain barrier to cytotoxicity (25, 29) .
We hypothesized that nanobodies could be tailored to modulate P2X7 function on macrophages and T cells in vivo and thereby provide therapeutic benefit in inflammatory diseases. We set out to generate highly specific P2X7 nanobodies (both antagonists and potentiators of P2X7 function) and test their efficancy in models of inflamation.
RESULTS

Immunization of llamas with P2X7 in native conformation yields potent functional nanobodies
To present the P2X7 ion channel in its native conformation to cells of the llama immune system, we applied two immunization strategies: human embryonic kidney (HEK) cells stably expressing P2X7 for one group of llamas (mouse P2X7) and intradermal complementary DNA (cDNA) immunizations with a gene gun followed by a boost with P2X7-transfected HEK cells for a second group of llamas (mouse P2X7 and human P2X7) (Fig. 1A) . Both groups showed P2X7-specific antibody responses (Fig. 1B) . To select nanobodies that recognize native mouse P2X7, we cloned nanobody-phage display libraries from the immunized animals and panned these libraries on P2X7-expressing cells. Sequence analyses of selected target-binding clones revealed enrichment of 18 nanobody families (table S1) .
To evaluate the capacity of nanobodies to modulate the function of P2X7, we used nucleotide-induced ectodomain shedding of CD62L by Yac-1 mouse lymphoma cells as a convenient readout ( fig. S1 ). Nanobodies from six distinct families either blocked or enhanced both ATP-mediated and nicotinamide adenine dinucleotide (NAD + )-mediated activation of P2X7. The most potent blocker, nanobody 13A7 [median inhibitory concentration (IC 50 ), 12 nM], and the most potent enhancer, nanobody 14D5 [median effective concentration (EC 50 ), 6 nM], were selected for further analyses. Flow cytometric analyses with transfected HEK cells verified specific binding of these nanobodies to mouse P2X7 but not to human P2X7, mouse P2X1, or mouse P2X4 (Fig. 1C) .
Dimerization enhances the potency of P2X7-modulating nanobodies
The single-domain format of nanobodies facilitates their assembly into dimers and multimers. Because P2X7 is a homotrimeric ion channel, we reasoned that dimerization of nanobodies would improve binding affinity and enhance functional potencies. Thus, we generated dimeric molecules of nanobodies 13A7 and 14D5 by genetically fusing two single domains via a flexible peptide linker (Fig. 2, A and B) . To provide half-life extension (HLE) for in vivo applications, we genetically fused homodimers of 13A7 and 14D5 to the albumin-binding nanobody Alb8, which causes the fused product to adopt the serum half-life of albumin in the respective host species (28 the nanobodies to the hinge and Fc domains of mouse IgG2c. Comparative dose-response analyses of monomeric 13A7 and 14D5 and their dimeric counterparts revealed 7-to 50-fold increases in P2X7-blocking and P2X7-enhancing potencies, respectively (Fig. 2, C and D) . The three different versions of bivalent nanobodies-nanobody-dimers, HLEdimers, and Fc fusions (Nb-Fc)-showed similar potencies. The 13A7 Nb-Fc format, a reconstituted heavy chain antibody, was more than 100 times more potent than four previously described P2X7-specific monoclonal antibodies (30) (31) (32) in blocking ATP-induced shedding of CD62L by mouse T cells (Fig. 2E) .
Bivalent nanobodies modulate ATP-induced ion channel function in P2X7-expressing cells Binding of extracellular ATP gates the P2X7 ion channel, resulting in a sustained influx of Ca 2+ and Na + and an efflux of K + . To measure the effect of P2X7-blocking (13A7) and P2X7-potentiating (14D5) nanobodies on ATP-induced P2X7 currents, we performed two-electrode voltage-clamp recordings on mouse P2X7-expressing Xenopus oocytes (Fig. 3A) . Oocytes responded to the application of ATP with the characteristic slow and sustained currents in the presence of control Nb-Fc fusion proteins. In the presence of 13A7-Fc, ATP application induced little, if any, detectable currents. In contrast, in the presence of 14D5-Fc, ATP-evoked currents displayed faster activation and higher current amplitudes.
In P2X7-transfected HEK293 cells, nanobody 13A7-dimer effectively blocked ATP-induced Ca 2+ influx, whereas 14D5-dimer potentiated ATP-induced Ca 2+ influx in these cells and sustained Ca 2+ influx even in response to low, subthreshold concentrations of ATP (Fig. 3B) . When added to cells already showing sustained ATPinduced Ca 2+ influx, 13A7-dimer reversed Fluo-4 (Ca 2+ indicator) signals, whereas 14D5-dimer further potentiated these signals (Fig. 3C) . Nanobody titration analyses revealed a dose-dependent blockade of P2X7, with similar subnanomolar IC 50 /EC 50 values for blockade/ potentiation of both ATP-induced Ca 2+ influx (Fig. 3D ) and ATPinduced shedding of CD62L (Fig. 2D ), confirming that nanobodies block different downstream effects of P2X7.
Monovalent and bivalent nanobodies 13A7 and 14D5 also effectively blocked or potentiated ATP-induced pore formation ( fig. S2A ). The effects of monovalent nanobodies 13A7 and 14D5 were readily reversed when cells were washed, whereas bivalent nanobodies showed continued functional effects even after washing, consistent with a slower rate of dissociation of bivalent nanobodies ( fig. S2A ). Further pharmacological characterization showed that the small-molecule P2X7 antagonist A438079 and nanobody 13A7 both blocked the potentiating effect of nanobody 14D5 on ATP-induced Ca fig. S3D ), but it did not affect P2X7-independent inflammasome assembly in response to the K + ionophore nigericin ( fig. S3B ). Dimeric nanobodies 13A7 and 14D5 also did not affect transcription of Il6 or Il1b genes in response to P2X7-independent activation of nuclear factor kB by LPS ( fig. S3E ). Treatment of primary T cells with dimeric nanobodies effectively blocked (13A7) or potentiated (14D5) ATP-induced shedding of CD27 ( fig. S4A ) and NAD-induced cell death ( fig. S4B ). In contrast, these nanobodies did not affect P2X7-independent proliferation of T cells in response to CD3-cross-linking antibodies ( fig. S4C ), confirming that the nanobodies act exclusively on P2X7-dependent cellular functions. Nanobody 13A7-HLE blocks P2X7 in vivo in mice and ameliorates allergic contact dermatitis To assess the capacity of nanobody 13A7 to reach and block P2X7 function on immune cells in vivo, we intravenously injected half-life-extended dimeric 13A7-HLE into the mice. Splenic T cells and peritoneal macrophages were recovered at different time points after nanobody injection and were challenged ex vivo with ATP to assess target occupancy and functional blockade. 13A7-HLE effectively blocked both ATP-induced shedding of CD27 by splenic T cells and ATP-induced nuclear DAPI (4′,6-diamidino-2-phenylindole) uptake by peritoneal macrophages within 2 hours of nanobody injection (Fig. 4 , A and B). Comparative analyses of dimeric (13A7-dimer) versus half-life-extended dimeric (13A7-HLE) nanobodies showed that fusion to the albumin-specific nanobody Alb8 resulted in a much longer blockade of P2X7 in vivo (Fig. 4C ). Blockade of P2X7 by 13A7-HLE was still effective 96 hours after injection (Fig. 4B ). Next, we probed the therapeutic potential of 13A7-HLE in a mouse model of allergic contact dermatitis in response to the contact allergen 1-fluoro-2,4-dinitrobenzene (DNFB). In this model, mice are sensitized by epicutaneous application of DNFB to the shaved abdominal skin (day 0). When challenged 6 days later with DNFB on the ear skin (day 6), mice respond with a characteristic local inflammatory response that can be monitored by the ear swelling reaction and the release of inflammatory cytokines 24 hours after challenge. Mice deficient for P2X7 are resistant to contact hypersensitivity, because dendritic cells fail to produce IL-1b in response to the contact allergen in the sensitization phase (8) . Therefore, 13A7-HLE was systemically administered on days 0, 3, and 6. Blocking P2X7 via 13A7-HLE ameliorated local inflammation, because animals treated with nanobody 13A7-HLE had a significantly lower gain in ear weight than did control animals and significantly lower levels of the inflammatory cytokines IL-6 and IL-1b in ear tissue extracts (Fig. 4D ). The therapeutic effect also required application of nanobodies during the challenge phase, because a single injection of 13A7-HLE before sensitization with DNFB did not significantly decrease inflammation (Fig. 4D ). This suggests that P2X7 plays a role during both the sensitization and challenge phases of the inflammatory response, consistent with the finding that application of the contact allergen to the ear causes local release of ATP (8) .
Nanobody 13A7-HLE ameliorates experimental glomerulonephritis in mice To further assess the therapeutic potential of nanobody 13A7-HLE in inflammatory diseases, we analyzed its effects in a mouse model of experimental glomerulonephritis induced by injection of antibodies against glomerular podocytes (33) . Before injection and every 3 days after injection of antipodocyte antibodies, we treated groups of mice with either 13A7-HLE, a control nanobody-HLE, or the P2X7-potentiating nanobody 14D5-HLE. We monitored disease progression using markers of renal function and acute inflammation, as well as by histological analyses of kidney sections. All animals receiving antipodocyte antibodies had deposits of immunoglobulin and complement component 3 along the basement membrane of glomerular capillaries ( fig. S5 ). Animals treated with 13A7-HLE showed little, if any, inflammation; animals treated with 14D5-HLE had enhanced inflammation and kidney damage (Fig. 5) . Albuminuria was significantly reduced after 15 days in animals treated with 13A7-HLE compared to animals treated with control nanobody-HLE (Fig. 5, A and B) . Nanobody 13A7-HLE prevented the development of nephrotic syndrome, maintaining normal levels of blood urea nitrogen, serum triglycerides, and serum cholesterol (Fig. 5D ), as well as preventing a rise of the proinflammatory cytokine IL-6 in serum and MCP-1 [monocyte chemoattractant protein-1 (MCP-1/ CCL2)] in urine (Fig. 5D ). Nanobody 13A7-HLE also inhibited histopathological signs of kidney damage, including tubular protein casts, glomerular capillary occlusion, swelling of podocytes, and disrupted nephrin staining at the filtration barrier (Fig. 5E ). Immunohistochemical analyses of inflammatory cells revealed significantly reduced infiltration of Ly6G + granulocytes and CD3 + T cells in the glomeruli of animals treated with 13A7-HLE compared to animals treated with control nanobody-HLE (Fig. 5F ). Conversely, animals treated with 14D5-HLE showed enhanced glomerular infiltration of granulocytes and T cells ( Fig. 5G ) and enhanced albuminuria (Fig. 5, A and B) . Nanobody 14D5-HLE did not cause any significant effects on disease progression in P2x7 −/− animals, confirming that the aggravating effect of this nanobody is mediated via P2X7 (Fig. 5C ). Together, these data demonstrate that the P2X7-antagonizing nanobody 13A7-HLE ameliorates inflammation in two distinct disease models.
Human P2X7-specific nanobody Dano1 blocks IL-1b release from endotoxin-exposed human monocytes Using human P2X7-expressing HEK cells for panning of phage display libraries, we selected a nanobody, designated Dano1, that recognizes human P2X7 with high specificity. Dano1 does not crossreact with mouse P2X7 or with human P2X1 or P2X4, the closest orthologs of P2X7 (Fig. 6A ). Dano1 blocked ATP-induced Ca 2+ influx and pore formation in these cells (Fig. 6B) , and dimerization reduced the IC 50 of Dano1 for ATP-induced Ca 2+ influx and pore formation by HEK cells from 0.5 to 0.2 nM (Fig. 6C) . Compared to the previously described human P2X7-antagonistic conventional monoclonal antibody (mAb) L4 (32), Dano1 demonstrated both higher potency (20-to 50-fold lower IC 50 ) and efficacy (>95% versus 60 to 70% maximal inhibition) (Fig. 6, B and C) .
Dano1 blocked ATP-induced inflammasome assembly by LPS-primed human monocytes (Fig. 7A) inflammasome assembly induced by nigericin (Fig. 7A ) nor P2X7-independent transcription of IL6 or IL1B in response to LPS (Fig. 7B) . Similarly, Dano1 effectively blocked ATP-induced shedding of CD62L and the externalization of phosphatidylserine by human T cells (Fig. 7C) but did not affect P2X7-independent proliferation of T cells in response to anti-CD3 antibodies (Fig. 7D) .
The critical role of P2X7 in release of the proinflammatory cytokine IL-1b underscores its importance as a therapeutic target in inflammation. To evaluate the potential therapeutic benefit of Dano1, we used a surrogate P2X7-mediated inflammation model and measured the release of IL-1b from monocytes in fresh human blood treated with LPS and ATP. Cells of all four healthy volunteer donors responded to this treatment with heightened secretion of IL-1b (Fig. 7 , E and F). Dano1 blocked ATP-induced release of IL-1b with subnanomolar IC 50 ( Fig. 7E) . Dano1 demonstrated up to 1000-fold higher potency than the small-molecule inhibitors of P2X7 currently in preclinical development for neurological and inflammatory diseases [JNJ47065567 (neurological diseases; Janssen) and AZ10606120 (renal injury; AstraZeneca)] (15, 16). Its high specificity and potency make Dano1 an excellent clinical candidate.
DISCUSSION
Our study describes highly potent nanobody antagonists of the mouse and human P2X7 ion channel with higher specificity, better pharmacodynamics, and lower toxicity than current small-molecule antagonists. These nanobodies represent the first effective biologic antagonists of this emerging drug target for inflammatory disease (15, 18) . In two different experimental mouse models of inflammatory diseases, antibody-induced glomerulonephritis and allergic contact dermatitis, systemic injections of the half-life-extended antagonist nanobody 13A7 ameliorated disease. In a surrogate inflammation model with endotoxin-exposed fresh human blood samples, the nanobody Dano1 blocked the release of the proinflammatory cytokine IL-1b with up to 1000-fold higher potency than small-molecule inhibitors of P2X7 currently in development for inflammatory and neurological diseases (15, 18) . −/− animals were used in one control experiment (C), and wild-type mice were used in all other experiments. Groups of mice (n = 6 to 10) were treated with P2X7-specific 13A7-dimer HLE or 14D5-dimer HLE or control nanobody-dimer HLE (2 mg/kg) 2 hours before serum injection and additionally every 3 days (1 mg/kg). Urine albumin levels (U alb ) were quantified by ELISA, and urine creatinine levels (U crea ) were determined by automated measurement (A to C). Data in (A) show means ± SEM from n = 6 to 8 animals. Data in (B) and (C) are from individual animals (n = 8 to 16), with means and SEM indicated by bars and vertical lines. On the day of killing, blood urea nitrogen (BUN), serum triglycerides, and serum cholesterol levels were determined by automated measurement; IL-6 in serum and MCP-1 in urine were quantified by ELISA (D). Data in (B) to (D) are endpoint values on day 15 . P values were determined by Mann-Whitney U test (n = 6 to 13). (E) Kidney sections were stained with periodic acid-Schiff. Tubular protein casts are marked by asterisks, and glomerular capillary occlusions and swollen podocytes are marked by arrows and arrowheads, respectively. Sections were also stained with the DNA staining dye draq5 and with antibodies against nephrin, a podocyte cell surface protein essential for the proper functioning of the renal filtration barrier (bottom) In contrast to small molecules, biologics exhibit high specificity and have few off-target effects. The duration of nanobody-mediated blockade of P2X7 in vivo could easily be tailored: although dimeric nanobodies blocked P2X7 in vivo for several hours, fusion to the antialbumin nanobody Alb8 provided long-term in vivo blockade of P2X7 for at least 4 days, reflecting the serum half-life of mouse albumin of ca. 2 days. Hence, the presence of the clinically validated albumin-binding module provides the nanobodies with good pharmacokinetics and pharmacodynamic properties in vivo and allows the translation from mouse models and non-human primates to man (34) . Clinical leads containing an albumin-binding module such as the anti-IL-6R nanobody ALX-0061 are being given every 2 to 4 weeks by subcutaneous injection for systemic lupus erythematosus and rheumatoid arthritis (NCT02437890 and NCT02287922). Nanobody Dano1 is applicable for the treatment of systemic human inflammatory disorders in which high levels of ATP and IL1b are found, including glomerulonephritis, lupus nephritis, and acute dermatitis. Previous pharmacological and genetic studies have already implicated P2X7 as a potential therapeutic target in glomerulonephritis, and an increase in glomerular expression of P2X7 was observed in renal biopsies from lupus nephritis patients, as well as in rat and mouse glomerulonephritis models (1, 7). Taylor et al. showed that rats treated with a small-molecule P2X7 antagonist as well as P2X7-deficient mice display attenuated inflammatory kidney damage in response to the injection of antibodies against the glomerular basement membrane (7). Our results corroborate the therapeutic potential of P2X7 antagonistic nanobodies in this indication, because 13A7-HLE inhibited renal immune cell infiltration and P2X7-dependent kidney pathology. Moreover, the finding that the P2X7-enhancing nanobody 14D5-HLE aggravated glomerular inflammation substantiates the pathological role of P2X7 in this disease. It should be noted that the P2X7 nanobodies have been administrated from the onset of inflammation because the mouse model progresses more rapidly and aggressively than the human disease, in which the nanobodies would be applied in a therapeutical setting, after disease was established. In the acute dermatitis inflammatory response, P2X7 evidently plays a role during both the sensitization and challenge phases, consistent with the finding that application of the contact allergen to the ear causes local release of ATP (8) . During the sensitization phase, P2X7 expression on dendritic cells is important for the activation of T cells (8) . Nanobody 13A7-HLE effectively prevented local inflammation and effectively blocked release of proinflammatory IL-6 and IL-1b when present during the challenge phase, suggesting that multiple P2X7-expressing immune subsets are involved. Both disease indications hence seem valid options for the application of P2X7 antagonist nanobodies.
In addition, inflammatory bowel disease is a potential indication, because P2X7 and IL-1b participate in both initiation and regulation of intestinal inflammation (21, 30) . P2X7 is differentially expressed in the mucosa of patients with active and quiescent inflammatory bowel disease. An increase in the number of colonic mast cells expressing P2X7 has been observed in patients with Crohn's disease and in a mouse model of experimentally induced colitis. In the latter, treatment with a mouse P2X7-specific antibody inhibited mast cell activation and intestinal inflammation (30) . Moreover, the small-molecule inhibitor of P2X7 AZD9056 showed improved clinical parameters in a phase 2 study in patients with moderate-to-severe Crohn's disease, although there was a lack of objective change in the biomarkers of inflammation (21) . It seems that AZD9056 modulated pain rather than the chronic inflammatory response in this setting, consistent with the evidence for a role of P2X7 in chronic pain (4, 5) .
Llama immunization also yielded another P2X7 nanobody, 14D5, that reduced the ATP threshold required for gating of mouse P2X7. In comparison to other P2X receptors, gating of P2X7 requires relatively high concentrations of ATP (35) . It is unknown whether such high concentrations can be achieved in extracellular compartments other than the immediate vicinity of necrotic cells. However, a number of substances including LL37, polymyxin B, and ivermectin potentiate gating of P2X7 in an allosteric manner (36, 37) . It is conceivable that 14D5 similarly allosterically facilitates the conformational change required for gating of P2X7. Systemic injections of 14D5-HLE aggravated disease parameters in the glomerulonephritis model. Although such proinflammatory effects would be undesired in a chronic inflammatory disease, enhancing P2X7-mediated inflammation might be therapeutically useful in other pathophysiological situations, for instance, in cancer or infections with intracellular parasites. The usefulness of nanobodies as specific modulators of P2X7 function in the clinic may be limited by three factors. First, common allelic variants affect the sensitivity of P2X7 to extracellular ATP (38, 39) .
P2X7 antagonist nanobodies could be more effective in patients expressing highly sensitive P2X7 variants. Although we have verified Dano1 efficacy in human immune cells from several donors, a full genotype analysis would be advisable before commencing clinical trials. Second, nanobodies have a low intrinsic propensity to cross the blood-brain barrier, similar to conventional antibodies, which restricts brain uptake and application to neurological disorders. For inflammatory diseases of the central nervous system, it may be necessary to engineer P2X7 antagonist nanobodies for improved crossing of the blood-brain barrier (29, 40) . Third, the development of antibodies to a nanobody in a patient is a potential limitation of any biologic. Although nanobodies have a high intrinsic sequence identity to human germ line V H (variable region of immunoglobulin heavy chain), lead candidates are further sequence-optimized for even lower immunogenicity (41) . The level of treatmentrelated antibodies toward nanobodies that have been tested in clinical trails is in the same range as that for marketed human and humanized antibodies (42) . Numerous examples of nanobodies in successful clinical development now exist, with eight different nanobodies currently in clinical trials, the most advanced being in phase 3 for thrombotic thrombocytopenic purpura (NCT02553317). Efficacy of nanobodies in inflammatory disease has been demonstrated in multiple clinical trials, including phase 2 trials of vobariluzumab directed against the IL-6 receptor for rheumatoid arthritis (34) and of caplacizumab directed against von Willebrand factor for acquired thrombotic thrombocytopenic purpura (NCT01284569 and NCT01020383) (42) . Our P2X7 antagonist nanobodies would likely follow a similar translational path to the clinic, after the successful assessment of the pharmacological and pharmacodynamic parameters and safety profile in preclinical species.
The nanobodies described here may represent the next generation of highly specific, long-acting P2X7 antagonist drugs. Given the central role of IL-1b in chronic inflammatory diseases, antagonizing P2X7 may be an attractive alternative or complementary strategy to blocking IL-1b. The modular nature of the nanobody technology allows the combination of nanobody modules with different specificities. Similarly, fusion to nanobodies that bind lineage-specific cell surface proteins may allow targeting of P2X7-specific nanobodies to specific cell types, such as regulatory T cells or inflammatory monocytes. In general, the strategy described here-llama immunization combined with nanobody development-may be useful for generating specific functional biologics against other leukocyte ion channels that are promising drug targets.
MATERIALS AND METHODS
Study design
Our study was designed to determine whether activation of the P2X7 ion channel can be inhibited in vitro and in vivo with anti-P2X7 nanobodies. We derived 19 new anti-P2X7 nanobodies. We identified one nanobody (13A7) that inhibits ATP-induced gating of mouse P2X7 and one nanobody (14D5) that potentiates ATP-induced gating of mouse P2X7 and one nanobody (Dano1) that inhibits ATPinduced gating of human P2X7. We used established preclinical inflammatory models to evaluate the inhibitory activity of mouse P2X7-specific nanobody 13A7 in vivo. Previous studies had demonstrated that disease in these models can be ameliorated by broad-spectrum P2X7 antagonists (7, 8) . In the mouse model of allergic contact dermatitis [delayed type hypersensitivity (DTH) model], an ear-swelling response is induced by painting the allergen DNFB onto the abdominal skin ("sensitization"), followed 6 days later by a second application of the allergen onto one ear ("challenge"). In the mouse model of glomerulonephritis (GN model), an inflammatory response is induced by injection of sheep anti-mouse podocyte antibodies, resulting in the deposition of antibodies and complement components along glomerular capillaries. The inflammatory response in the DTH model can be quantified conveniently 24 hours after the challenge by the gain in ear weight and the local release of the inflammatory cytokines IL-1b and IL-6. In the GN model, the loss of albumin to the urine serves as an indicator of damage to the glomerular filtration barrier and the appearance of neutrophils and T cells in glomeruli as an indicator of the local inflammatory response. To ensure a sustained blockade of P2X7 throughout the course of these aggressive disease models, we injected half-life-extended dimeric nanobodies 2 hours before induction of disease and, again, every 3 days after induction of disease. Dosage and timing of nanobody administration were determined by pharmacodynamic simulation studies aiming to maintain a serum concentration of 100 nM for the half-life-extended nanobodies (100-fold above the IC 50 ), on the basis of previously determined in vivo half-life for HLE-dimeric nanobodies of 1.3 to 1.9 days. Animals were killed after 7 days (DTH model) or 15 days (GN model), that is, at the expected peak of the respective inflammatory responses.
To evaluate the inhibitory activity of the human P2X7-specific nanobody Dano1 in vivo, we used a surrogate inflammation model in which fresh samples of human blood were treated sequentially with endotoxin (LPS) and ATP. This induces a massive, P2X7-dependent release of IL-1b, providing a means to test the therapeutic potential of Dano1 in inflammation. Mice were assigned randomly to experimental groups. The sample size was determined by power analyses. Studies were blinded. Numbers of replicates are indicated in the figures or in the corresponding legends for all experiments.
Selection and characterization of P2X7-specific Nanobodies Phage libraries were selected in suspension on Chinese hamster ovary cells transfected with mouse P2X7. Bound phages were eluted by trypsinization, amplified in TG1 Escherichia coli, and reselected on Yac-1 cells endogenously expressing mouse P2X7. Single colonies were picked for screening of monovalent nanobodies by phage ELISA on fixed cells, after which positive hits were sequenced. For each unique sequence, protein expression was induced with isopropyl-b-D-thiogalactopyranoside for 3 hours during exponential growth. Periplasmic lysates were generated by osmotic shock and removal of bacterial debris by high-speed centrifugation. Nanobodies in crude periplasmic extracts were screened for selective binding to P2X7-transfected HEK cells by flow cytometry, either directly or after preincubation of extracts with fluorescein isothiocyanate-labeled anti-c-myc mAb (clone 9E10) for 30 min to form nanobody-anti-tag mAb complexes.
Multivalent formatting of Nanobodies
Homodimeric bivalent nanobodies were constructed by PCR using a 35-GS linker (GGGGS) 7 to fuse the two nanobodies. Half-lifeextended nanobody formats were constructed using PCR by fusing the homodimeric nanobody via a 9-GS linker (GGGGSGGGG) to a third nanobody, Alb8, an albumin-specific nanobody (28) . The Nb-Fc fusion format was generated by subcloning the VHH coding sequence upstream of the hinge and Fc domains of mouse IgG2c in the pCSE2.5 eukaryotic expression vector (provided by T. Schirrmann, Technical University Braunschweig, Germany) (43) . Monovalent, bivalent, and HLE nanobodies were expressed as c-myc-His6x-tagged proteins in either E. coli, Pichia pastoris strain X-33, or HEK-6E cells (44) and purified by immobilized metal affinity chromatography using Ninitrilotriacetic acid beads (45) . Fc fusion proteins were expressed in HEK-6E cells and purified by affinity chromatography using protein G-Sepharose (GE Healthcare).
Ectodomain shedding and cell death by Yac-1 cells and murine and human T cells Anti-CD3 (145-2C11), anti-CD4 (RM4-5 and RPA-T4), anti-CD8 (RPA-T8), anti-CD25 (PC61), and anti-CD62L (MEL-14 and DREG-56) were obtained from BD; anti-CD27 (LG.3A10) was from BioLegend. Cells were preincubated with P2X7-specific or control nanobodies for 15 min at 4°C and then further incubated for 20 min at 37°C in RPMI medium in the absence or presence of ATP (46, 47) . Cells were washed, stained with fluorochrome-conjugated antibodies, and analyzed by flow cytometry (FACSCanto II, BD; and FlowJo software, Tree Star). For cell death analyses, T cells were stained with fluorochrome-conjugated annexin V (BD) and antibodies in annexin V-binding buffer for 20 min, washed, and analyzed by flow cytometry in the presence of propidium iodide (Sigma).
T cell proliferation assays
Mouse CD4 T cells were purified from spleen and peripheral lymph nodes by negative selection using magnetic beads (Miltenyi). Cells were labeled with 2 mM carboxyfluorescein succinimidyl ester (CFSE; Invitrogen) for 30 min at 37°C. Cells were washed and preincubated in complete RPMI medium (supplemented with 10% fetal calf serum, L-glutamine, pennicilin, and streptomycin; all from Gibco) in the absence or presence of nanobodies for 20 min before seeding onto a 24-well plate coated with anti-CD3 and anti-CD28 (each at 1 mg per well; BD) at 5 × 10 5 cells per well. Proliferation of T cells was analyzed after 3 days by CFSE dilution by flow cytometry. Human peripheral blood mononuclear cells were labeled with 2 mM eFluor 670 (eBioscience) for 10 min at 37°C. Cells were washed and resuspended in complete RPMI medium in the absence or presence of anti-CD3 (400 ng/ml; OKT3, BioLegend). Cells were seeded onto a round-bottom 96-well plate at 80,000 cells per well in the absence or presence of nanobodies at a final concentration of 100 nM. Nanobodies were added a second time after 2 days of culture. After 4 days, cells were stained with anti-CD4 (RPA-T4) and anti-CD8 (SK1), and proliferation of living T cells was analyzed by eFluor dye dilution by flow cytometry.
Experimentally induced allergic contact dermatitis Three groups (n = 8) of adult 9-to 10-week-old female C57BL/6J mice were sensitized by two applications in a 24-hour interval of DNFB (Aldrich) (30 ml of a 0.5% solution in acetone/olive oil, 4:1; Acros Organics) to the shaved abdominal skin. Two hours before the first application, two groups of mice received intraperitoneal injections of half-life-extended, Alb8-fusion proteins of nanobody 13A7 or a control nanobody [3 mg/kg in 200 ml of phosphate-buffered saline (PBS)]. These mice received one further intraperitoneal injection of the respective half-life-extended nanobodies on day 3 and an intravenous injection on day 6, 2 hours before challenge (both at a concentration of 3 mg/kg). The third group of mice received dexamethasone (200 mg/200 ml; Sigma) per os on day 6, 2 hours before challenge. Mice were challenged by the application of DNFB (20 ml of 0.2% solution in acetone/olive oil) to the right ear. As control, mice received applications of solvent (20 ml of acetone/olive oil, 4:1) to the left ear. Mice were killed 24 hours after challenge, and the disease course was monitored by measuring ear weight. The disease score is represented as the difference in ear weight of the right ear (treated with DNFB) and the left ear (treated with solvent). IL-6 and IL-1b in lysates of challenged und unchallenged ears were determined by ELISA. Allergic contact dermatitis experiments were performed by Washington Biotechnology Inc., Bethesda, MD.
Experimentally induced antipodocyte nephritis
Groups of C57BL/6J mice (n = 6 to 10) received intravenous injections of antipodocyte serum or preimmune serum (200 ml; concentrated twofold by centrifugation through centrifugal filters) (33) , preceded by intravenous injections of half-life-extended nanobodies (2 mg/kg in 100 ml of saline). The mice received further intraperitoneal injections of half-life-extended nanobodies (1 mg/kg in 1 ml of saline) every 3 days. Urine was collected in metabolic cages for 4 to 6 hours after nanobody injection. Disease course was monitored by proteinuria using qualitative urine sticks. Mice were killed on day 15 or 21. Albumin and MCP-1 in urine and IL-6 in serum were quantified by sandwich ELISA (Bethyl, eBioscience) (33) . Urine creatinine, blood urea nitrogen, serum triglycerides, and serum cholesterol were determined by an automated procedure in the central diagnostic laboratory of the University Medical Center Hamburg. For detection of T cells and granulocytes, 2-mm-thick paraffin sections obtained from kidneys fixed in 4% formalin were deparaffinized and rehydrated to water. Antigen retrieval was performed by digestion with protease XXIV (5 mg/ml; Sigma) for 15 min at 37°C (for Ly6G staining) or by boiling in citrate buffer (pH 6.1) for 30 min at 98°C (for CD3 staining). Unspecific binding was blocked by incubation with blocking buffer [5% normal horse serum (Vector) in PBS-0.05% Triton X-100] for 30 min at room temperature. Primary antibodies [rabbit anti-CD3 (1:1000; Dako) and rat anti-Ly6G (1:400; Hycult Biotech)] were incubated overnight at 4°C in blocking buffer. Visualization of staining was performed using the ZytoChem Plus AP Polymer Kit (Zytomed Systems) according to the manufacturer's instructions using neufuchsin (Merck). Nuclei were counterstained with hemalaun (Merck). CD3 + and Ly6G + cells in glomeruli were quantified in 10 high-power visual fields (400×) per kidney in 6 to 10 mice per experimental group of n = 3 independent experiments. A visual field comprised one to three glomeruli.
Statistical analysis
Statistical analyses were performed with GraphPad Prism. Two groups were compared with Mann-Whitney U or Student's t test. Three or more groups were analyzed by one-way ANOVA, followed by Bonferroni posttests.
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